Genomic imprinting is an inherited epigenetic phenomenon that results in parental ± origin ± speci®c gene expression in somatic cells. Relaxation or loss of this feature in certain genes has been demonstrated in several pediatric and adult neoplasms, suggesting an association with tumorigenesis. We analysed 64 primary untreated head and neck squamous carcinoma for the loss of imprinting in the IGF2 and H19 genes to determine the implications of this alteration in the development and progression of these tumors. Forty-nine (77%) of the 64 tumors were informative for imprinting analyses of these genes. IGF2 and H19 were imprinted in all normal squamous epithelium examined. Twelve (37.5%) of 32 tumors informative for H19 and 11 (40.7%) of 27 tumors informative for IGF2 manifested loss of imprinting. Ten tumors were informative for both genes, of which four maintained the constitutional imprinting and six showed loss of imprinting at either H19 or IGF2. These data suggest that loss of imprinting at the IGF2 and H19 loci play a role in the oncogenesis of head and neck carcinoma.
Introduction
HNSC is the sixth most frequent cancer worldwide, with an estimated 30 750 new cases and 8440 deaths reported in the United States in 1997 (American Cancer Society, 1997; Parkin et al., 1988) . Despite eorts to improve early diagnosis and treatment for this disease, the overall survival of patients remains low. Determining the genetic and epigenetic alterations that underlie the development and progression of these tumors may not only provide a better understanding of the biologic changes in HNSC during tumorigenesis, but may also identify novel diagnostic and prognostic markers. HNSC is an ideal model for investigating the epigenetic alterations due to their accessibility throughout progression. Molecular studies of these tumors, however, focused on the DNA alterations and minimal eorts limited to studies of the methylation status of the p16 gene were expended (Ah-See et al., 1994; ElNagger et al., 1995a ElNagger et al., ,1996b ElNagger et al., , 1997 Herman et al., 1995; Papadimitrakopoulou et al., 1998; Pershouse et al., 1997; Reed et al., 1996) .
Genomic imprinting is de®ned as gamete of origin chromosomal modi®cation that leads to the dierential expression of parental alleles of a gene in somatic cells (Bartolomei, 1994; Ezzell, 1994; Feinberg, 1993; Vrana et al., 1998; Neumann et al., 1995; Peterson and Sapienza, 1993) . Recent studies indicate that this epigenetic phenomenon plays signi®cant roles in both normal development and oncogenesis (Cattanach and Beechey, 1990; Crouse, 1996; DeChiara et al., 1991; Reeve et al., 1989; Swain et al., 1987) . This is based on the preferential LOH in selective parental chromosomal loci and the loss of constitutional imprinting at certain genes in several tumors Fukuzawa et al., 1999; Hibi et al., 1996; Kim et al., 1998; Dao et al., 1987; Kondo et al., 1995; McCann et al., 1996; Nonomura et al., 1997; Oda et al., 1998; Ouyang et al., 1997; Ross et al., 1999; Steenman et al., 1994; Suzuki et al., 1994; Temple et al., 1995; Wu et al., 1997) . Imprinting abnormalities may contribute to tumorigenesis either by activation of a transcriptionally repressed allele of a growth-promoting oncogene or by inactivation of a parentally expressed allele of an imprinted tumor suppressor gene (Bartolomei, 1994; Ezzell, 1994; Feinberg, 1993; Barlow, 1997; Oda et al., 1998; Neumann et al., 1995; Peterson and Sapienza, 1993; Steenman et al., 1994; Temple et al., 1995; Mitsuya et al., 1997) . Alternatively, these alterations may constitutionally precede and therefore predispose to, or promote, tumorigenesis as evinced by the compatibility of constitutional imprinting alterations with the non-malignant kidney phenotype in patients with Wilms' tumor (Chao et al., 1993; Morrison et al., 1996) .
Genes subject to genomic imprinting are typically clustered in a region of hundreds of kilobases (Greally et al., 1998; Lee et al., 1999; Rainier et al., 1993) . One of these regions is located on chromosome 11p15 and contains a large domain of imprinted genes with growth-promoting (IGF2) and control (p57 kip2 and H19) functions (Chung et al., 1996; Dao et al., 1999; Lee et al., 1999; Sabbioni et al., 1997) . IGF2, a 67-amino acid peptide, is a paternally expressed insulinlike growth factor with autocrine growth function. H19 is a maternally expressed gene that lacks an evolu-tionary conserved open-reading frame and functions as an RNA molecule (Steenman et al., 1994) . The high incidence of LOI that results in the biallelic expression of IGF2 and/or reduced H19 expression has been reported in several pediatric and adult malignancies and is considered to play a role in their development and progression (Christofori et al., 1994; Cui et al., 1997; Fukuzawa et al., 1999; Kim et al., 1998; Nonomura et al., 1997; Oda et al., 1998; Ross et al., 1999; Suzuki et al., 1994; Thompson et al., 1996; Van Roozendaal et al., 1998) . The purpose of this study was to assess: (1) the imprinting status of IGF2 and H19 genes in HNSC; and (2) if imprinting alterations are present in tumor and matched normal mucosa.
Results
The status of imprinting of H19 and IGF2 was determined in 64 untreated primary HNSCs by RT ± PCR followed by restriction-site polymorphism analysis for H19 (RsaI) and IGF2 (ApaI, HinfI). Fifteen tumors were noninformative for both genes and were excluded from further analysis. Of the remaining 49 tumors, DNA from 32 (65%) and 27(55%) were heterozygous at H19 and IGF2, respectively. No PCR product was obtained by either AS, S or P2, P3 primers pairs in negative RT ± PCR control (data not shown). By restriction analysis of RT ± PCR products, monoallelic expression was observed in all the normal squamous mucosa for both genes. In contrast, biallelic expression was detected in 12 of 32 tumors at H19 (38%) and in 11 of 27 (41%) tumors at IGF2 (Table 3) . Of the ten tumors that were informative at both genes, four maintained imprinting at both loci and three each showed reciprocal LOI at IGF2 and H19 (Table 4) . None of the tumors showed simultaneous LOI at both loci. Analysis of genomic DNA for H19 and IGF2 heterozygosity for subsequent imprinting analyses are illustrated in Figures 1 and 2 ; heterozygosity for H19 is noted in cases 18, 19, 24, 27, 28 and 29, whereas cases 17, 20 ± 23, 25, 26 and 30 show homozygosity ( Figure  1 ). IGF2 heterozygosity is demonstrated by the presence of two bands in cases 43, 44, 46, 51 and 52 (Figure 2) . Figure 3 presents H19 imprinting analysis of HNSCs. Cases 49 and 50 manifested monoallelic expression in both normal and corresponding tumor specimens, indicating that they retained constitutional imprinting. Cases 42, 44 and 57 displayed three bands in tumor samples representing loss of imprinting but only two bands in corresponding normal tissues. In some samples (cases 44, 50 and 57) faint bands at approximately 655 bp size were noted only in normal mucosa but not in the corresponding tumor. However, the main bands from these specimens (407 and 168 bp) were the expected products of the RsaI enzyme digestion of the cDNA. These faint bands may represent either minimal genomic DNA contamination or the presence of low frequency mosaic cells with active paternal allele in normal mucosa. Figure 6 depicts the imprinting results of IGF2 in cases 46, 49, and 57. The digested cDNA (Figure 4) shows monoallelic expression of IGF2 in normal and tumor Figure 1 Analysis of H19 heterozygosity. RsaI digestion of a 655-bp PCR product yielded bands of 487 and 168-bp (cases 17, 20, 23, 25, 26) or 655-bp (cases 21, 22, 30), indicating homozygosity. Heterozygous specimens (cases 18, 19, 24, 27, 28, 29) showed all three bands (G1) and RT ± PCR (Cu) ampli®cation using primers P1 and P3 and DNA ampli®cation by PCR with primers P2 and P3 (G2). (b), Digested normal tissue DNA PCR(Gc) from primers P2 and P3 showed heterozygosity. The digested nested PCR product from primers P2 and P3 using the 1.12-kb RT ± PCR product as a template showed monoallelic expression of IGF2 in normal (Nc) and tumor (Tc) tissues from cases 46 and 57. Biallelic expression of IGF2 is noted in the tumor tissue of case 49 tissues from cases 46, 57 and biallelic expression of IGF2 is noted in tumor sample of case #49. There was no apparent correlation between LOI in H19, IGF2 and the clinicopathologic factors analysed (Table 1) .
Discussion
Although several studies of imprinting abnormalities in adult malignancies have been carried out, little is known regarding the involvement of this epigenetic alteration in HNSC. We investigated for the ®rst time the imprinting status of the H19 and IGF2 genes located on chromosome 11p15 in 64 untreated primary HNSCs to determine the incidence of LOI and its presence in normal mucosa. Our results show that LOI in both H19 and IGF2 are manifested in approximately 40% of the tumors while all corresponding normal mucosa lacked similar alterations of these genes. The incidence of LOI is similar to those reported in dierent adult neoplasms Kondo et al., 1995; Suzuki et al., 1994; Wu et al., 1997) but is slightly lower than that found in other carcinomas (McCann et al., 1996; Nonomura et al., 1997; Oda et al., 1998; Rainier et al., 1993) . Although we cannot completely exclude the possibility that this epigenetic event might be a manifestation of a genome-wide breakdown, our data and those of others, indicate that LOI is a nonrandom and specific aberration associated with the development of HNSC and other tumors (Reik et al., 1995a,b; Uyeno et al., 1996) .
Studies of neuroblastoma and hepatoblastoma, however, failed to reveal epigenetic abnormalities in both genes (Hibi et al., 1996; Montagna et al., 1994; Wada et al., 1995) favoring the selective nature of this 9  11  13  15  16  18  19  21  23  24  26  27  28  29  30  31  32  33  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  55  56  57  58  61  63  64   58  69  39  67  68  47  42  62  46  59  54  68  61  68  61  69  43  56  56  46  35  67  59  67  77  52  50  70  85  75  61  51  52  53  55  68  58  87  60  55  27  63  36  70  68  56  53  46 58 PD  PD  MD  PD  WD  PD  PD  PD  WD  MD  PD  MD  MD  PD  MD  MD  MD  MD  PD  N  MD  MD  WD  MD  PD  WD  WD  PD  MD  MD  PD  MD  MD  MD  PD  PD  WD  MD  PD  MD  PD  WD  WD  WD  PD  PD   II  IIIB  IIC  IV  III  IIB  IIB  II  IIB  IIB  II  II  II  II  IIB  I  IV  II  III  III  II  IV  II  I  III  III  III  I  II  II  II  II  II  III  II  II  IV  IIB  II  II  IV  IIB  II  II  II  II  II  III process and indicate that the incidence of LOI appears to be neither uniform nor consistent among tumors. Our data also revealed reciprocal LOI of the H19 and IGF2 in the majority of heterozygous tumors for both genes and suggest that imprinting of these genes may be a tissue organ-and/or tumor-speci®c process (DeChiara et al., 1991; Jinno et al., 1994; Van Roozendaal et al., 1998; Verkerk et al., 1997) . In contrast to studies of Wilms' tumor, sporadic hepatoblastoma and rhabdomyosarcoma (Fukuzawa et al., 1999; Hao et al., 1993; Rainier et al., 1993; Steenman et al., 1994) , the presence of biallelic expression of H19 in our study and others (Li et al., 1997; Rachmilewitz et al., 1996; Verkerk et al., 1997) may argue against a tumor suppressor role in favor of an oncogene-like function for this gene (Kim et al, 1998; Li et al., 1997; Mannens et al., 1994) . However, the lack of correlation between the expression level of H19 and LOI in some studies suggest that a tumor suppressor function cannot be ruled out (Zhan et al., 1995) . In that context, it is possible that partial LOI of the paternal allele may lead to down regulation of the maternal allele and low overall expression or alternatively to other genetic and/or epigenetic events that may act independently in the regulation of the expression of H19 (Kondo et al., 1995; Nonomura et al., 1997) .
We and others have previously demonstrated an association between LOH at chromosome 11p15.5 and aggressive characteristics and high proliferation of HNSC (El-Naggar et al., 1996; Montagna et al., 1994; Rainier et al., 1993; Suzuki et al., 1994) . However, the lack of association between LOI and any of the clinicopathologic features in this study suggests a role independent of tumor progression as reported in lung and breast carcinomas and glioma (Cui et al., 1997; DeChiara et al., 1991; Van Roozendaal et al., 1998) . It is possible, therefore, that up-regulation of these genes may promote proliferation in the early development of a subset of these neoplasms. This is evinced by the hyperproliferation associated with imprinting disruption in experimental islet cell tumorigenesis (Christofori et al., 1995) and the correlation between LOI and aggressive features in renal cell carcinoma and myeloid leukemia (Nonomura et al., 1997; Randhawa et al., 1998) . Taken together these results further underscore the variable oncogenic and biologic eects of imprinting alterations in dierent tumor types.
In summary, our data indicate that LOI of IGF2 or H19 may constitute a novel mechanism of the deregulation of growth promoting genes in the development of HNSC (Baylin, 1997) . Future analysis of imprinting in preinvasive squamous lesions should determine the timing of this abnormality and its role in the evolution of these tumors.
Materials and methods

Tissues
The panel of tissues analysed consisted of matched pairs of fresh frozen normal mucosa and tumor specimens from 64 primary HNSCs that were resected before any other treatment. Normal mucosa was obtained from the farthest margin of resection after frozen section veri®cation. Invasive carcinoma specimens were carefully dissected from grossly viable tumor and were subjected to frozen section for the evaluation of tumor content. Specimens with less than 70% neoplastic elements were excluded from this study. All specimens were obtained and histologically assessed by one pathologist (A El-Nagger) and kept in an 7808C freezer until use.
DNA extraction
Frozen tissue was homogenized by a tissue tearor (Biospec Products, Bartlesville, OK, USA) and incubated for 3 h in a lysis buer containing 1% SDS, 0.1 M NaCl, 50 mM EDTA (pH 8.0), and 200 mg/ml proteinase K. DNA was then puri®ed using standard procedures with phenol/chloroform and precipitated with ethanol (Cui et al., 1997) .
RNA extraction
Tumor tissue was grounded and lysed in 1 ml guanidinium isothiocyanate-phenol solution (RNAzol B, Biotecx Laboratories. Inc., Houston, TX, USA), and 100 ml chloroform was added to sample lysates. Specimens were then centrifuged and the aqueous RNA-containing phase was precipitated with an equal volume of isopropanol. The pellet was resuspended with 30 ml DEPC-H 2 O and treated with Rnase-free DNaseI (BRL, Baltimore, MD, USA) at a concentration of 0.1 u/ml for 15 min at room temperature to eliminate DNA contamination. DNaseI was then inactivated by the addition of 1 ml 25 mM EDTA to the reaction mixture and heating for 10 min at 658C. RNA concentration was determined spectrophotometrically (Pharmacia, Alameda, CA, USA). To assess the integrity of extracted materials, RNA analysis was electrophoretically performed under denaturing conditions on 2% agarose with 6% formaldehyde gel.
Genomic PCR ampli®cation
Primers AS and S (Table 2 and Figure 5 ) were used to amplify DNA for the H19 gene . The resultant 655-bp PCR product was subject to RsaI digestion, yielding additional 487-bp and 168-bp bands in heterozygotes by 2% agarose gel and 6% acrylamide gel (Figures 1, 5 and were also used to get a 1.4 kb DNA fragment that was used as a size control for the RT ± PCR product (Figure 4 ). Conditions for AS and S ampli®cation were 988C for 5 min followed by 35 cycles at 948C for 1 min, 588C for 1 min, and 728C for 1 min. This was terminated by an elongation step of 728C for 5 min. PCR conditions for primers P2 and P3 were the same as those for the AS-S primer pair except for an annealing step of 598C for 1 min. Dierences in PCR conditions for primers P1 and P3 compassed with primers AS and S were an annealing step of 568C for 2 min and extension at 588C for 3 min.
RT ± PCR
Tissue samples identi®ed as being heterozygous at H19 or IGF2 were further analysed for possible allele-speci®c expression. One microgram total RNA from normal and tumor samples was reverse transcribed for the ®rst strand cDNA using the Gene Amp RT ± PCR system (Perkin-Elmer Cetus, Branchburg, NJ, USA, in a 20 ml reaction. This reaction mixture was added to 80 ml of 100 mM dNTP and 2 mM MgCl 2 , 10% glycerol and 2.5 units Taq polymerase (Perkin-Elmer) in 16PCR buer. Ampli®cation was carried out with 0.4 mm primer (AS and S) at 948C for 1 min, 648C for 1 min, 728C for 1 min (35 cycles), and 728C for 5 min for ®nal extension. This resulted in an obvious 575 bp PCR band from cDNA compared to the control of 655 bp fragment from genomic DNA which includes 80 bp intron (Figure 3 ). For IGF2 ampli®cation with primers P1 and P3, PCR conditions were the same except for a 1.5-min annealing step at 608C. The PCR product was analysed on 1.5% agarose gel to verify the 1.12 kb RT ± PCR bands, which were smaller than those observed in DNA analysis (1.4 kb) with the inclusion of 280 bp intron. Nested PCR was continued with the primer P2 as P3 from this 1.12-kb RT ± PCR product, resulting in a 292-bp band (Davies, 1993) ( Figure 4 ). For negative PCR controls, the same primers and reaction conditions with RNA, minus the reverse transcription step were performed.
LOI
For samples heterozygous for the H19 RsaI polymorphism, the corresponding RT ± PCR products were restricted with RsaI to assess allelic expression. Constitutive imprinting yielded either a single 575-bp band or 407-and 168-bp bands ( Figure 5 ). LOI resulted in 575-bp, 407-and 168-bp fragments. Digestion of control genomic DNA resulted in 655 bp and/or 487, 168 bpm bands, on 6% acrylamide gel electrophoresis after silver staining (Pierce, Rockford, IL) ( Figure 3 ). For IGF2, ApaI and HinfI were used to digest the 292-bp cDNA product from the above nested PCR reaction. The presence of 256-bp and 231-bp fragments in a tumor sample on 2.5% agarose gel indicated biallelic expression (Figures 4 and 6) . The presence of either the 256-bp or 231-bp band was considered as retention of imprinting.
Statistical analysis
The correlation between LOI and gender, age, site tumor grade, nodal status, clinical stage, DNA ploidy and S phase (58.0%) was performed using Fisher's exact test.
Figure 5 H19 gDNA structure and imprinting map. DNA ampli®cation using primers S and AS yielded a 655-bp fragment for subsequent heterozygosity analysis. RT ± PCR from these primers provided a 575-bp cDNA fragment for imprinting analysis Figure 6 IGF2 gDNA structure and imprinting map. DNA ampli®cation using primers P1 and P3 resulted in 1.4-kb DNA fragment and a 1.12-kb cDNA fragment. Primers P2 and P3 were used to amplify DNA for heterozygosity analysis and nested cDNA for allelic expression 
